These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 24376578)

  • 1. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
    Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
    PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
    Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
    Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
    Wan Y; Wu W; Yin Z; Guan P; Zhou B
    BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.
    Duan X; Li J
    Medicine (Baltimore); 2017 Sep; 96(36):e7856. PubMed ID: 28885338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
    Yang Y; Xia T; Li N; Zhang J; Yang Y; Cong W; Deng Q; Lan K; Zhou W
    Protein Cell; 2013 Jan; 4(1):71-81. PubMed ID: 23292895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
    Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
    Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
    Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
    Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between TP53 Arg72Pro polymorphism and hepatocellular carcinoma risk: a meta-analysis.
    Xu CT; Zheng F; Dai X; Du JD; Liu HR; Zhao L; Li WM
    Asian Pac J Cancer Prev; 2012; 13(9):4305-9. PubMed ID: 23167333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Chang HY; Ahn SH; Kim JK; Park YK; Kang DR; Park JY; Myoung SM; Kim DY; Chon CY; Han KH
    Carcinogenesis; 2008 Jun; 29(6):1192-6. PubMed ID: 18390844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
    Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
    Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
    Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
    Liu GY; Jiang DK; Shen SQ; Yu L
    Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
    Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA
    Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
    Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
    Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
    Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
    Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.